Overview of Caldeoss

Property	Description
Active Ingredients	Calcium Carbonate, Dihydrotachysterol
Form	Oral Tablets
Pharmacological Class	Calcium Supplement, Vitamin D Analog
General Purpose	Correcting or preventing calcium deficiency
Origin	Mineral Salt (Natural), Synthetic Seco-steroid Analog (Synthetic)

What Type of Medicine is Caldeoss?

Caldeoss is a combination pharmaceutical product classified as both a Calcium Supplement and a Vitamin D Analog. This medicine is typically provided as an oral tablet and functions by addressing the need for both the essential mineral and the agent that promotes its effective absorption. The formulation's primary component, Dihydrotachysterol, falls under the grouping of Vitamin D and analogues (A11CC02). The structural combination of a mineral salt and a synthetic seco-steroid analog ensures a targeted, integrated approach to mineral management, a necessity clinically recognized for patients requiring enhanced control over their calcium levels.

What is the Composition of Caldeoss?

The primary active ingredients in Caldeoss are Calcium Carbonate and Dihydrotachysterol. Calcium Carbonate is an inorganic salt that provides a high-yield source for elemental calcium, the mineral necessary for bone and physiological function. The second compound, Dihydrotachysterol (DHT), is a synthetic analogue of vitamin D. This compound is known to enhance the body's use of calcium, especially in cases where the body's natural activation of standard Vitamin D may be impaired. This specific combination is often classified as a prescription-only (Rx) product due to the potent nature of Dihydrotachysterol compared to other over-the-counter calcium preparations.

What is the General Purpose of Caldeoss?

The general purpose of Caldeoss is to stabilize and raise serum calcium levels by supplying the mineral and enhancing the body's mechanisms for its use. The combined action is designed to provide potent support for the regulation of calcium and phosphate metabolism. For instance, it is commonly used in scenarios where rapid and consistent management of low blood calcium (hypocalcemia) is required. This formulation provides a differentiating factor by offering a Vitamin D Analog that is less dependent on normal kidney function for activation than some other Vitamin D forms.

Regulatory References

hypocalcemia

What side effects are possible with Caldeoss?

Possible Side Effects and Safety Information

The safety profile of Caldeoss (Calcium Carbonate, Dihydrotachysterol) is principally defined by the risk of hypercalcemia (abnormally high blood calcium levels), which is the most significant adverse reaction documented in official regulatory labeling. Adverse effects are grouped by the body system affected, according to regulatory standards.

Official Adverse Reactions by System-Organ Class

Adverse reactions classified as common in regulatory documents often relate to the gastrointestinal and metabolic systems. These may include constipation, nausea, abdominal cramps, and early signs of elevated calcium such as polydipsia (increased thirst) and polyuria (frequent urination).

System-Organ Class	Common Adverse Effects	Less Common Adverse Effects
Metabolism & Nutrition	Hypercalcemia
Gastrointestinal	Constipation, Nausea, Abdominal Cramps
Nervous System		Headache, Lethargy, Mental Confusion
Renal & Urinary	Polyuria, Polydipsia	Nephrocalcinosis

Serious Adverse Reactions and Safety Constraints

The most serious adverse reactions are associated with severe or prolonged uncontrolled hypercalcemia. These include the potential for a life-threatening hypercalcaemic crisis and the risk of irreversible renal damage due to the progressive calcification of soft tissues. The development of widespread soft-tissue calcification is specifically noted in regulatory safety data as a consequence of persistent, uncontrolled elevated calcium levels.

Regulatory labeling highlights specific safety constraints, including the mandatory requirement for regular monitoring of blood calcium levels throughout treatment. The risk of developing hypercalcemia is known to be particularly elevated during the initial phase of treatment and following dosage adjustments. Furthermore, the co-administration of other Vitamin D preparations or large doses of calcium supplements is explicitly warned against due to the significantly increased safety risk.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Caldeoss (Calcium Carbonate, Dihydrotachysterol) is primarily defined by manifestations of hypercalcemia and associated Vitamin D toxicity, as documented in government regulatory labeling.

Documented Manifestations and Outcomes

Symptoms officially documented in overdose cases may include early signs such as anorexia, nausea, vomiting, constipation, polyuria (increased urination), and polydipsia (increased thirst). More severe presentations involve neurological changes like somnolence, confusion, and in extreme cases, coma. Severe, life-threatening outcomes include cardiac arrhythmias, hypertension, and widespread calcification of soft tissues, leading to renal impairment or renal failure.

Official Emergency Actions

The regulatory guidance mandates that individuals seek immediate medical attention or contact emergency services if severe symptoms are suspected or if signs of collapse, trouble breathing, or inability to be awakened occur. Urgent medical evaluation and hospitalization are required for suspected severe hypercalcemia.

Management and Monitoring

No specific antidote is known for this overdose. Management relies on corrective symptomatic and supportive treatment, including immediate withdrawal of the medication, hydration (often intravenous), and the use of medications such as diuretics or bisphosphonates to reduce serum calcium. Frequent monitoring of serum calcium levels and ECG monitoring are required due to the risk of cardiac complications.

Therapeutic Uses of Caldeoss

The primary therapeutic use of this combination mineral supplement and Vitamin D analog is applied in addressing conditions associated with systemic imbalance by providing essential supportive mineral management. The medication is commonly used in conditions presenting with symptoms related to systemic imbalance where systemic imbalance requires additional therapeutic support.

Caldeoss is applied in clinical settings that involve acute or unstable symptom patterns, primarily managing Hypoparathyroidism and Pseudohypoparathyroidism, and is commonly used across conditions presenting with acute or disruptive episodes like Renal Osteodystrophy and Refractory Rickets. The medication contributes to maintaining a sense of stability during symptomatic periods, providing support that helps ease the overall symptom burden of these chronic deficiencies. It is relevant in conditions characterized by periods of heightened symptoms associated with systemic or chronic deficiencies.

“Supports the patient during difficult episodes by easing distress caused by symptoms related to systemic imbalance.”

This combination is used to help address symptom clusters that may become intense or disruptive, such as muscle tetany, painful cramping, and widespread paresthesias (tingling sensations). It is commonly used to help with symptoms of increased neurological or muscular activity that create noticeable physiological strain. The therapy contributes to easing the overall symptom load by assisting with maintaining functional stability through supporting processes related to bone mineralization.

Quick Fact: Support for Symptoms of Increased Neurological or Muscular Activity
Supports the patient during episodes of increased neurological or muscular activity, helping to ease distress caused by symptoms like tetany and muscle cramping.

Eligibility and Restrictions for Use

The official regulatory criteria for using Caldeoss (Calcium Carbonate, Dihydrotachysterol) establish clear limitations based on a patient’s existing metabolic state and physiological status.

Eligibility Scope

Classification	Population or Condition
Contraindicated	Patients with Hypercalcemia (high calcium levels), Vitamin D toxicity, Hypersensitivity to components, Nephrolithiasis (renal stones), or Hypercalciuria (excessive urinary calcium).
Not Recommended	Patients with severe renal impairment or renal failure. Women who are breastfeeding.
Use with Caution	Patients with Coronary Artery Disease or Arteriosclerosis; use requires careful monitoring.
Not Established	Children under 18 years of age for most standard indications.

Adult patients with conditions such as Hypoparathyroidism or Renal Osteodystrophy are the standard labeled population for use. Use during pregnancy is restricted and only recommended if the potential benefit is determined to outweigh the potential risk to the fetus. The restrictions collectively ensure the medicine is not used in individuals whose pre-existing metabolic state would be worsened by its calcium-regulating effects.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Caldeoss (Calcium Carbonate, Dihydrotachysterol), based strictly on government regulatory documents.

Pharmacodynamic and Mineral Toxicity Risk

Co-administration with other Vitamin D Analogs and pharmacologic doses of Vitamin D is formally contraindicated due to the severe, additive risk of hypercalcemia and hyperphosphatemia. Caution is specifically required with Cardiac Glycosides (like Digoxin), as Caldeoss-induced hypercalcemia can potentiate the digitalis effect, increasing the risk of cardiac arrhythmias. Thiazide Diuretics may also exacerbate hypercalcemia due to an additive effect on calcium retention.

Pharmacokinetic Exposure and Timing Rules

The Calcium Carbonate component can reduce the systemic exposure (bioavailability) of several co-administered medicines through physical binding (chelation) in the gastrointestinal tract. Affected medicines include Tetracycline and Quinolone antibiotics, Bisphosphonates, Levothyroxine, and Estramustine. Official documentation mandates that the administration of these drugs must be staggered by specific time intervals to mitigate this reduction in systemic exposure.

Metabolic and Food Substance Interference

The Dihydrotachysterol component is subject to metabolic interference by CYP3A4 inhibitors, such as Grapefruit Juice, which may increase the drug’s plasma concentrations. Additionally, the absorption of Calcium Carbonate may be decreased by consuming foods high in oxalic or phytic acid (e.g., spinach, bran), also requiring separation of dose timing. Monitoring is required for patients with renal or hepatic impairment, as these conditions may alter the metabolic activity and toxicity risk associated with the drug's components.

Mechanism of Action

Blockade of L-type Calcium Channels

Caldeoss acts as a direct antagonist of the L-type Ca^2+ channels, which are critical regulators of muscle contraction in the heart and blood vessels. This action prevents the influx of extracellular calcium into these cells, suppressing the signaling sequence that leads to muscle activation and thereby modifies signaling dynamics in cardiovascular tissues.

Modulation of Vascular Smooth Muscle Tone

By blocking calcium entry, Caldeoss promotes the relaxation and widening of the arteries, a process called vasodilation. This mechanism is relevant in systems where targeted pathway adjustment is required to reduce peripheral vascular resistance, which consequently increases flow conductance within the systemic vasculature.

Control of Cardiac Activity and Oxygen Requirement

The drug also engages mechanisms that influence the Ca^2+ signaling necessary for myocardial contractility and electrical conduction within the heart. Modifying these early molecular steps supports a regulated state in key pathways by reducing the heart's pumping force and slowing its rate, thereby reducing the myocardial oxygen requirement.

Dosage and Administration Information

How to Use Caldeoss: Official Administration Guidelines

This section outlines the official, high-level principles for using Caldeoss (Calcium Carbonate and Dihydrotachysterol).

Administration Scope

Instruction	Detail
Route of administration	Oral intake only (via tablet or solution).
Dosing schedule (Adults)	Initial Dose: 0.8 mg to 2.4 mg Dihydrotachysterol equivalent once daily for a short phase. Maintenance Dose: 0.2 mg to 1 mg Dihydrotachysterol equivalent once daily.
Timing in relation to meals	Generally taken with a meal to enhance the absorption of the calcium component.
Preparation requirements	Solid dosage forms must be swallowed whole with water.
Age-group administration rules	Neonates and Children require specific, weight-based initial and maintenance daily regimens. No specific dose adjustment guidelines for hepatic or renal impairment are consistently provided across official labels.
Missed-dose rules	Patients are instructed not to double the dose to compensate for a dose that was missed.
Special procedural conditions	The regimen requires adequate co-administration of elemental calcium (provided by the Calcium Carbonate component) to be used as labeled, and treatment necessitates regular laboratory monitoring for dose adjustment.

Instruction Classifications (High-Level)

Classification	Detail
Administration method type	Oral solid dosage (Tablet) or Oral liquid dosage.
Frequency pattern	Once daily (for both initial and chronic maintenance phases).
Use-context constraints	Titration-dependent (dose adjustments occur at 4 to 8 week intervals); Calcium-dependent (must be administered with sufficient elemental calcium).

Resulting Procedural Structure

The official instructions establish a precise, two-phase oral administration protocol consisting of a short, high-dose initial phase followed by a long-term, chronic maintenance phase. This protocol is defined by a once-daily frequency and a requirement for co-administration of calcium, standardizing the use across adult and pediatric populations. The official guidance mandates a long titration period between dose adjustments, thereby structuring the regimen as a closely monitored, time-dependent process.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Caldeoss

Research has been conducted on the components of Caldeoss (Calcium Carbonate and Dihydrotachysterol) in the context of calcium and mineral imbalances. The research describes the types of outcomes that were examined, the groups of people who were studied, and what aspects of long-term use are not fully characterized by the existing data. Studies are conducted to examine temporary physiological imbalance and how outcomes related to physical discomfort evolve in observed populations.

Evidence for Use in Hypoparathyroidism

Research has explored the use of this therapy’s components in the context of chronic forms of Hypoparathyroidism, a condition involving systemic or functional imbalance due to low Parathyroid Hormone levels. Studies include systematic reviews and long-term observational studies that tracked patients over many years. The core focus was on tracking serum calcium and phosphate levels against established targets and what measurements were recorded against target ranges. Research also monitored the evolution of outcomes related to episodic changes, such as acute muscle spasms (tetany) and cramping, which are forms of heightened symptom activity. The existing evidence highlights the need for careful follow-up due to the metabolic profile of the Vitamin D component, as evidence suggests that managing the risk of high calcium levels (hypercalcemia) requires continuous attention.

Evidence for Use in Renal Osteodystrophy

The components of Caldeoss were studied in the context of bone and mineral issues, such as Renal Osteodystrophy, in people with chronic kidney problems. The evidence base includes prospective, randomized, controlled trials (RCTs) where Dihydrotachysterol was compared against other similar active Vitamin D analogs. These studies examined populations with mineral metabolism disorders related to chronic kidney issues. Researchers tracked changes in linear growth (measured by height) in children, as well as the status of kidney function itself. The evidence highlights that the use of this class of medicine was associated with the observation of changes in kidney health during the study.

What Research Still Needs to Clarify about Caldeoss

Key limitations noted in the literature include the focus of many studies on surrogate markers (like blood chemistry) rather than direct patient-reported outcomes or functional measures. Specifically, long-term effects are not fully established regarding the reduction of significant clinical events, such as bone fractures. Furthermore, comparative evidence is lacking in certain areas, meaning that the full scope of how this therapy compares to all newer or alternative treatments is not fully characterized by the current evidence.

Key Studies & References

Evaluation and Management of Hypoparathyroidism Summary Statement and Guidelines from the Second International Workshop

Frequently Asked Questions (FAQ)

Common questions about Caldeoss (FAQ)

Q: Is Caldeoss the same as similar-sounding over-the-counter supplements?

A: Caldeoss is a combination pharmaceutical product containing Calcium Carbonate and Dihydrotachysterol, a potent Vitamin D Analog. Official documents classify this formulation as a prescription-only (Rx) medicine. This status is due to the nature and strength of the Dihydrotachysterol component, which distinguishes it from standard, over-the-counter calcium preparations.

Q: Which food or drinks might interact with Caldeoss?

A: Official regulatory documents describe a few food and drink interactions. Grapefruit Juice may interfere with the way the Dihydrotachysterol component is processed by the body. Additionally, the absorption of the calcium component may be reduced by consuming foods high in oxalic or phytic acid, such as spinach or bran products.

Q: Can Caldeoss be taken alongside vitamins or other supplements?

A: According to official product information, taking Caldeoss with other Vitamin D Analogs or large doses of Vitamin D is strictly contraindicated. This is due to a severe, increased risk of dangerously high blood calcium levels (hypercalcemia). There are no general contraindications noted in official labeling for common non-D vitamins or non-mineral supplements.

Q: Is Caldeoss known to interact with commonly used blood pressure medicines?

A: Regulatory documents mention caution is required with certain heart and blood pressure medicines. Specifically, Thiazide Diuretics may increase the risk of hypercalcemia. Caution is also advised regarding Cardiac Glycosides (like Digoxin), as Caldeoss-induced hypercalcemia may potentiate the digitalis effect, which carries an increased risk of heart rhythm issues.

Q: What kind of studies have been done on Caldeoss?

A: The research evidence cited in official documents includes various types of studies. These include prospective, randomized, controlled trials (RCTs), systematic reviews, and long-term observational studies. The core focus of these studies has been tracking metabolic outcomes, such as changes in patients' serum calcium and phosphate levels.

Q: Is Caldeoss available as a generic medicine?

A: Caldeoss is a brand name. However, the active component Dihydrotachysterol is also available in generic pharmaceutical products for certain indications. The availability of generic versions is subject to local regulatory frameworks.

Q: Why does the packaging for Caldeoss have a Black Box Warning (or similar high-level safety alert)?

A: Official safety documents do not always use the term 'Black Box Warning,' but they do highlight significant safety constraints. This includes the mandatory requirement for regular laboratory monitoring of blood calcium levels throughout treatment. This level of caution is noted in the regulatory documents due to the significant and well-documented risk of severe hypercalcemia (abnormally high calcium in the blood).

Q: Can Caldeoss affect the results of blood tests?

A: Yes, official safety information states that the medicine is known to affect key laboratory values. Regulatory documents mandate the regular monitoring of blood calcium and phosphate levels throughout treatment. This is because Caldeoss is used to regulate and may elevate these levels.

Q: Is Caldeoss safe to use during pregnancy, according to official documents?

A: Official documents describe Dihydrotachysterol as being assigned to Pregnancy Category C. Its use during pregnancy is restricted and is only recommended in official labeling when the potential benefit is determined to outweigh the potential risk to the fetus.

Q: Can Caldeoss be taken while breastfeeding, based on official information?

A: According to official product information, Caldeoss is Not Recommended for use by women who are breastfeeding. This caution is based on a lack of available data concerning whether or not Dihydrotachysterol is excreted into human milk and the potential effects on the nursing infant.

Q: Is Caldeoss considered a 'high-risk' medicine?

A: While regulatory documents do not use the specific phrase 'high-risk,' they emphasize the drug's potent nature and serious safety profile. This is evident through the potential for life-threatening hypercalcemia and the mandatory requirement for continuous laboratory monitoring during treatment.

Q: How quickly do people typically start to feel a change after starting Caldeoss?

A: The official dosing protocol involves a long titration period, meaning dose adjustments occur over several weeks (typically 4 to 8 week intervals). This suggests that the therapeutic effect is not immediate. Caldeoss is administered as a long-term, chronic maintenance process that requires regular monitoring to manage calcium levels.

Q: Are there any long-term effects of taking Caldeoss for many years?

A: The most serious long-term effect documented in official safety information is the potential for irreversible renal damage (kidney damage). This risk is specifically associated with the progressive calcification of soft tissues resulting from persistent, uncontrolled high calcium levels in the blood.

Q: Do older adults typically experience different side effects from Caldeoss?

A: Official information for similar Vitamin D analogs often indicates that the risk of high blood calcium (hypercalcemia) is generally higher in older adults. Official guidance emphasizes the need for careful monitoring and dose adjustment in this group due to the potentially higher risk profile.

Q: Can Caldeoss cause changes in mood or sleep?

A: Side effects reported in official regulatory documents include central nervous system (CNS) effects such as Lethargy and Mental Confusion. These adverse reactions are changes related to a person's mental state and could potentially affect mood or alertness.

Q: Is there a maximum time someone can stay on Caldeoss?

A: Official administration guidelines establish a two-phase protocol that includes a long-term, chronic maintenance phase. This indicates that the medicine's administration protocol is defined by continuous, extended use.

Q: What if I forget to take Caldeoss for a few days?

A: The official documentation provides a rule for a single missed dose, instructing patients not to double the dose. The procedure for forgetting the medicine for multiple days in a row is not explicitly covered in patient-facing instructions and is not addressed by the single-dose rule in patient information.

Q: Is Caldeoss a controlled substance?

A: According to official classifications from regulatory bodies, Caldeoss (Dihydrotachysterol) is not listed as a controlled substance under the U.S. Controlled Substances Act (CSA) or similar international classifications. It is categorized as a prescription-required (legend) medicine.

Q: How is the long-term benefit of Caldeoss described in clinical trials?

A: Research supporting the medicine describes long-term benefit in terms of tracking and maintaining serum calcium and phosphate levels within established target ranges. Benefits also include a reduction in the occurrence of acute muscle spasms (tetany) and cramping in specific patient populations.

How should Caldeoss be stored and disposed of?

How to Store and Dispose of Caldeoss

Official regulatory documents define specific conditions necessary to maintain the quality and stability of Caldeoss.

Storage Requirement	Details
Temperature	Do not store the medicine above 25 C.
Protection	Keep the tablets in the original packaging to protect them from moisture.
Stability	Do not use this medicine after the expiry date printed on the container.
Child Safety	Keep this medicine out of the sight and reach of children.
Disposal	Do not throw away any medicines via wastewater or household waste; ask a pharmacist how to discard unused product.

The container should be kept tightly closed to maintain protection. The official disposal instructions prohibit discarding the product through general residential waste systems.

Caldeoss